Centre Leon Berard
Quick facts
Marketed products
- Firmagon · Oncology
- VEC · Oncology
VEC is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
Phase 3 pipeline
- BRN01 · Oncology
BRN01 is a small molecule targeting the CDK4/6 pathway. - cicaderma + simple hygiene rules · Dermatology
Cicaderma is a topical treatment that combines cicatricial and anti-inflammatory properties to promote wound healing and improve skin hydration. - Cocculine® · Gastroenterology / Symptom Management
Cocculine is a homeopathic preparation traditionally used to alleviate nausea and motion sickness symptoms. - Imatinib maintenance · Oncology
Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation. - interruption of Glivec® · Oncology
Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. - Pazopanib Oral Tablet [Votrient] · Oncology
Pazopanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT. - Placebo of AFATINIB
This is a placebo control arm and contains no active pharmaceutical ingredient. - Vesanoid · Other
Phase 2 pipeline
- Breast cancer cohort · Oncology
This drug targets the HER2 protein to inhibit cancer cell growth. - Carboplatin AUC7 · Oncology
Carboplatin works by interfering with DNA replication in cancer cells, leading to cell death. - HDM201
- Imatinib tablets · Oncology
Tyrosine kinase inhibitor - Immunological and tumour characterization
- Injection of Filgrastim · Oncology
Filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection. - Injection of Pegfilgrastim
- Lung cancer cohort
- NP137
- Velbe-Bleomycin-Cisplatin
- Vepeside-ifosfamide-Cisplatin
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: